Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection
出版年份 2013 全文链接
标题
Vaccine-induced monoclonal antibodies targeting circumsporozoite protein prevent Plasmodium falciparum infection
作者
关键词
-
出版物
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 1, Pages 140-144
出版商
American Society for Clinical Investigation
发表日期
2013-12-01
DOI
10.1172/jci70349
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Immune mechanisms in malaria: new insights in vaccine development
- (2013) Eleanor M Riley et al. NATURE MEDICINE
- Four-Year Efficacy of RTS,S/AS01E and Its Interaction with Malaria Exposure
- (2013) Ally Olotu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Complete Plasmodium falciparum liver-stage development in liver-chimeric mice
- (2012) Ashley M. Vaughan et al. JOURNAL OF CLINICAL INVESTIGATION
- Validation of an enzyme-linked immunosorbent assay for the quantification of human IgG directed against the repeat region of the circumsporozoite protein of the parasite Plasmodium falciparum
- (2012) Frederic Clement et al. MALARIA JOURNAL
- A Phase 3 Trial of RTS,S/AS01 Malaria Vaccine in African Infants
- (2012) NEW ENGLAND JOURNAL OF MEDICINE
- Real-time PCR-based assay to quantify the relative amount of human and mouse tissue present in tumor xenografts
- (2011) Sergio Y Alcoser et al. BMC BIOTECHNOLOGY
- Effect of the Pre-erythrocytic Candidate Malaria Vaccine RTS,S/AS01E on Blood Stage Immunity in Young Children
- (2011) Philip Bejon et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and efficacy of the RTS,S/AS01 E candidate malaria vaccine given with expanded-programme-on-immunisation vaccines: 19 month follow-up of a randomised, open-label, phase 2 trial
- (2011) Kwaku Poku Asante et al. LANCET INFECTIOUS DISEASES
- Efficacy of RTS,S/AS01E malaria vaccine and exploratory analysis on anti-circumsporozoite antibody titres and protection in children aged 5–17 months in Kenya and Tanzania: a randomised controlled trial
- (2011) Ally Olotu et al. LANCET INFECTIOUS DISEASES
- From the circumsporozoite protein to the RTS,S/AS candidate vaccine
- (2010) Joe Cohen et al. Human vaccines & immunotherapeutics
- Safety, Immunogenicity and Duration of Protection of the RTS,S/AS02D Malaria Vaccine: One Year Follow-Up of a Randomized Controlled Phase I/IIb Trial
- (2010) Pedro Aide et al. PLoS One
- The RTS,S malaria vaccine
- (2010) Sofia Casares et al. VACCINE
- Randomized, Double‐Blind, Phase 2a Trial of Falciparum Malaria Vaccines RTS,S/AS01B and RTS,S/AS02A in Malaria‐Naive Adults: Safety, Efficacy, and Immunologic Associates of Protection
- (2009) Kent E. Kester et al. JOURNAL OF INFECTIOUS DISEASES
- Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data
- (2009) Vasee S Moorthy et al. MALARIA JOURNAL
- Functional immunoassays using an in-vitro malaria liver-stage infection model: where do we go from here?
- (2009) Brent L. House et al. TRENDS IN PARASITOLOGY
- Host Cell Traversal Is Important for Progression of the Malaria Parasite through the Dermis to the Liver
- (2008) Rogerio Amino et al. Cell Host & Microbe
- Plasmodium falciparummalaria vaccines in development
- (2008) Johan Vekemans et al. Expert Review of Vaccines
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of Age
- (2008) Philip Bejon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Immunogenicity of RTS,S/AS02D Malaria Vaccine in Infants
- (2008) Salim Abdulla et al. NEW ENGLAND JOURNAL OF MEDICINE
- IMGT/V-QUEST: the highly customized and integrated system for IG and TR standardized V-J and V-D-J sequence analysis
- (2008) X. Brochet et al. NUCLEIC ACIDS RESEARCH
- Gene Disruption of Plasmodium falciparum p52 Results in Attenuation of Malaria Liver Stage Development in Cultured Primary Human Hepatocytes
- (2008) Ben C. L. van Schaijk et al. PLoS One
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More